MedTrace Logo

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

NCT07078591 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-07-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether HLA-mismatched donor G-CSF mobilized peripheral blood mononuclear cell (GPBMC) infusion with venetoclax-containing regimens (microtransplant, MST) could improve survival in adult patients with newly diagnosed acute myeloid leukemia (AML).

Conditions

Interventions

DRUG

Venetoclax

Given PO

DRUG

Azacitidine (AZA)

Given SC

DRUG

Daunorubicin

Given IV

DRUG

Idarubicin（IDA）

Given IV

DRUG

Cytarabine (Ara-C)

Given IV

BIOLOGICAL

GPBMC infusion

HLA-mismatched donor GPBMC infusion

Sponsors & Collaborators

  • Beijing 302 Hospital

    lead OTHER

Principal Investigators

  • Bo Cai, MD · Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-20
Primary Completion
2030-06-30
Completion
2031-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07078591 on ClinicalTrials.gov